ea0089t7 | Trials In Progress | NANETS2022
Singh, MD Simron
, Capdevila, MD, PhD Jaume
, Ang Chan, MD Jennifer
, de Herder, MD Wouter
, Ferone, MD, PhD Diego
, Halperin, MD Daniel
, Mailman, MBA Josh
, Hellstrom, MSc Lisa
, Svedberg, MSc, MBA Agneta
, Tiberg, PhD Fredrik
Background: Somatostatin analogues (SSAs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. Yet, disease progression may occur despite standard-dose SSA treatment, requiring more aggressive and toxic therapies. Retrospective/non-randomized data suggest higher-dose SSAs may benefit patients with GEP-NET who do not respond to standard-dose treatment a...